Recently, to reduce pharmaceutical expenditure, a combination of 2 SMIs blocking 2 mutated genes (BRAF and MET) are performed in the unique formulation (encorafenib + binimatenib) for melanoma therapy. The gene discussed is BRAF; the disease is melanoma.